Keywords: Sanofi-Aventis, Cabazitaxel, Prostate cancer, J&J, Medivation, Research
Sanofi-Aventis reports Ph III data on cabazitaxel, improving survival 30%, making it a strong contender in prostate cancer market
Article | 05 March 2010
French drug major Sanofi-Aventis has reported results from a Phase III trial which demonstrated that its cabazitaxel, an investigational compound, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
